Dr. MiltieAtlas by Dr. Miltie™Healthcare Grant Intelligence

My Organization Fit Score

See how strongly this opportunity fits your organization.

Atlas combines public grant intelligence with the details of your organization to evaluate eligibility, strategic alignment, funding potential, timing, project fit and submission burden.

GrantNIH PRIMED-AI Data-to-Model Academic-Industrial Partnerships (RFA-RM-27-012)
Atlas Opportunity Score92/100
FundingNIH anticipates 6-8 awards. Direct-cost limits are $450,000 per year in the UG3 phase and $800,000 per year in the UH3 phase.
DeadlineEarliest submission date September 19, 2026. Application due October 19, 2026 at 5:00 PM local time of the applicant organization. Late applications are not accepted.
Required next actionReview RFA-RM-27-012, confirm the required academic-industry partnership structure, required attachments, budget limits, and submission package, then submit by October 19, 2026 at 5:00 PM local time of the applicant organization. NIH states late applications will not be accepted.
Current statusOpenSource verificationOctober 1, 2026

Tell Atlas Who You Are

Request your organization-specific analysis.

The form will carry the grant context with it, so you only need to provide the details Atlas cannot know from the opportunity itself.

How Atlas Scores Fit

Useful enough to guide action, structured enough to scale.

01

Eligibility

Applicant type, geography, program rules and required conditions.

02

Strategic Alignment

How directly the organization's goals and use case match the funder's priorities.

03

Funding Potential

Available dollars, allowable uses, match burden and the amount that can realistically support the project.

04

Actionability

Deadline, documentation burden, readiness and the practical work required to submit a strong application.

A High Score Is the Beginning

When the fit is strong, Atlas shows you why.

The goal is not to hand you another number. It is to identify the opportunities worth your attention and make the next step obvious.